NCT03088527View on ClinicalTrials.gov

Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 23, 2017

Primary Completion Date

August 28, 2020

Study Completion Date

September 24, 2020

Conditions
Hormone Receptor Positive Malignant Neoplasm of Breast
Interventions
DRUG

RAD140

RAD140 will be supplied as formulated drug-in-capsules for oral administration.

Trial Locations (5)

37203

Sarah Cannon Research Institute, Nashville

48201

Barbara Ann Karmanos Cancer Center, Detroit

63110

Washington University School of Medicine, St Louis

06510

Yale Cancer Center, New Haven

02114

Cancer Center Protocol Office, Boston

All Listed Sponsors
lead

Stemline Therapeutics, Inc.

INDUSTRY

NCT03088527 - Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer | Biotech Hunter | Biotech Hunter